Thailand's National Drug Control Board will develop medicines based on psilocybin mushrooms. Medicines will be used in the treatment of various mental disorders.
Thai Justice Minister Somsak Thepsuthin said that psilocybin mushrooms have been used in traditional Thai medicine as a cure for insomnia. And clinical trials of the entheogen, conducted in the UK and the US, speak of its ability to alleviate symptoms of depression, anxiety and post-traumatic stress disorder (PTSD). Moreover, the psychedelic helps to overcome dependence on alcohol, drugs and tobacco.
In addition to the staff of the National Council of Thailand, specialists from Khon Kaen University will work on the implementation of the psilocybin drug project. They will start cultivating the magic mushroom strain Het Khee Khwai, which most likely means the Thai strain of Psilocybe Cubensis Pink Buffalo. Grown mushrooms are used as raw materials for the production of medicines for various ailments.
Thepsuthin denied speculation about the upcoming lifting of the ban on the use of psilocybin mushrooms for recreational purposes, noting that this offense, as now, will be punished by imprisonment for up to 1 year and a fine of up to 20,000 baht. However, in order to launch the entheogen treatment program, the government would have to legalize medical psilocybin. In this case, magic mushrooms will follow in the footsteps of medicinal cannabis, which was legalized in Thailand in 2018.
A curious fact is that the Thais decided to follow the American example and lift the ban on medical psilocybin. In May, US authorities announced their intention to allow the use of a psychedelic to combat depression within 24 months, and MDMA to relieve symptoms of PTSD. As a result, the US Drug Enforcement Division will be forced to reclassify psilocybin and ecstasy as narcotics of medicinal value.
Unlike their American counterparts, Thai officials have not set a clear timeline for the psilocybin therapy initiative. It appears that the speed at which psychedelics will be integrated into the health care system will depend on the results of drug testing with psilocybin.